Identifying the strains of dengue circulating in the western province of Sri Lanka during 2019-2022

A study conducted from July 2019 to May 2022 at several hospitals in the Western Province, Sri Lanka, focused on dengue virus strains during the COVID-19 pandemic. Among 417 febrile patients, 47% were PCR-positive for dengue. Serotyping revealed DENV-1 (12.8%), DENV-2 (46.4%), DENV-3 (37.2%), and DE...

Full description

Saved in:
Bibliographic Details
Published in:PLOS global public health Vol. 4; no. 7; p. e0003150
Main Authors: Abeygoonawardena, Harshi, Dassanayake, Kanchana, Kariyawasam, Jayani, Chathuranga, Teshan, Sundralingam, Tharmini, Gunasekara, Hansani, Wevita, Sathyani, Premawansa, Gayani, Premawansa, Sunil, Wijewickrama, Ananda, Wijesinghe, Namal, Navaratne, Varuna, Weiskopf, Daniela, Sette, Alessandro, Punchihewa, Chandanamali, De Silva, Aruna Dharshan
Format: Journal Article
Language:English
Published: United States Public Library of Science 2024
Public Library of Science (PLoS)
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A study conducted from July 2019 to May 2022 at several hospitals in the Western Province, Sri Lanka, focused on dengue virus strains during the COVID-19 pandemic. Among 417 febrile patients, 47% were PCR-positive for dengue. Serotyping revealed DENV-1 (12.8%), DENV-2 (46.4%), DENV-3 (37.2%), and DENV-4 (3.6%). Sequencing identified two genotypically distinct variants of DENV-3 and two genotypically distinct variants of DENV-1, while DENV-2 showed a single genotype cluster. Notably, the study found concurrent circulation of two DENV-3 and two DENV-1 genotypes, along with DENV-2, during the pandemic in the area. This data suggests the presence of multiple dengue strains, including several DENV-1 and DENV-3 variants, without major epidemic outbreaks reported in the Western Province. Continuous monitoring and research are essential to understand the dynamics of these dengue strains in the context of the COVID-19 pandemic.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
I have read the journal’s policy and the authors of this manuscript have the following competing interests: Daniela Weiskopf is a consultant for Moderna and AD De Silva was paid as a consultant by Genelabs Medical/ Takeda in the past. The other authors declare that they have no competing interests.
ISSN:2767-3375
2767-3375
DOI:10.1371/journal.pgph.0003150